MX2017004639A - Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt. - Google Patents

Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.

Info

Publication number
MX2017004639A
MX2017004639A MX2017004639A MX2017004639A MX2017004639A MX 2017004639 A MX2017004639 A MX 2017004639A MX 2017004639 A MX2017004639 A MX 2017004639A MX 2017004639 A MX2017004639 A MX 2017004639A MX 2017004639 A MX2017004639 A MX 2017004639A
Authority
MX
Mexico
Prior art keywords
compounds
signalling pathway
wnt signalling
pathway inhibitors
acetamide derivatives
Prior art date
Application number
MX2017004639A
Other languages
English (en)
Inventor
Inder Bhamra
Mathieson Michael
Donoghue Craig
Testar Richard
Original Assignee
Redx Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1417832.1A external-priority patent/GB201417832D0/en
Priority claimed from GBGB1512279.9A external-priority patent/GB201512279D0/en
Application filed by Redx Pharma Plc filed Critical Redx Pharma Plc
Publication of MX2017004639A publication Critical patent/MX2017004639A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención está relacionada a compuestos; más específicamente, la invención está relacionada a compuestos útiles como inhibidores de la vía de señalización Wnt; específicamente, los inhibidores de Porcupino (Porcn) son contemplados en la invención; además, la invención contempla procesos para preparar los compuestos y usos de los compuestos; los compuestos de la invención pueden por lo tanto ser utilizados en el tratamiento de condiciones mediadas por la vía de señalización Wnt, por ejemplo, para tratar cáncer, sarcoma, melanoma, cáncer de piel, tumores hematológicos, linfoma, carcinoma, y leucemia; o mejorar la efectividad de un tratamiento anti-cáncer.
MX2017004639A 2014-10-08 2015-10-08 Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt. MX2017004639A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417832.1A GB201417832D0 (en) 2014-10-08 2014-10-08 Compounds
GBGB1512279.9A GB201512279D0 (en) 2015-07-14 2015-07-14 Compounds
PCT/GB2015/052943 WO2016055790A1 (en) 2014-10-08 2015-10-08 N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors

Publications (1)

Publication Number Publication Date
MX2017004639A true MX2017004639A (es) 2017-07-17

Family

ID=54337305

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004639A MX2017004639A (es) 2014-10-08 2015-10-08 Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.

Country Status (20)

Country Link
US (4) US10202375B2 (es)
EP (2) EP3204381B1 (es)
JP (1) JP6588976B2 (es)
KR (1) KR102476667B1 (es)
CN (1) CN106795157B (es)
AU (1) AU2015329788B2 (es)
BR (1) BR112017007218B1 (es)
CA (1) CA2961740C (es)
DK (1) DK3204381T3 (es)
ES (1) ES2922580T3 (es)
HR (1) HRP20220864T8 (es)
HU (1) HUE059537T2 (es)
LT (1) LT3204381T (es)
MX (1) MX2017004639A (es)
PL (1) PL3204381T3 (es)
PT (1) PT3204381T (es)
RS (1) RS63397B1 (es)
SG (1) SG11201702142UA (es)
SI (1) SI3204381T1 (es)
WO (1) WO2016055790A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017004639A (es) * 2014-10-08 2017-07-17 Redx Pharma Plc Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.
EP3204378B3 (en) 2014-10-08 2022-05-25 Redx Pharma PLC N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2017189647A1 (en) * 2016-04-26 2017-11-02 Memorial Sloan Kettering Cancer Center Methods and compositions for the treatment of myelodysplastic syndrome
WO2019157085A2 (en) * 2018-02-06 2019-08-15 Vanderbilt University INHIBITION OF WNT/β-CATENIN SIGNALING IN THE TREATMENT OF OSTEOARTHRITIS
PL3762368T3 (pl) 2018-03-08 2022-06-06 Incyte Corporation ZWIĄZKI AMINOPIRAZYNODIOLOWE JAKO INHIBITORY PI3K-γ
CN108752366B (zh) * 2018-06-14 2019-10-18 绍兴文理学院 一种对甲基取代含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用
CN108752365B (zh) * 2018-06-14 2019-10-18 绍兴文理学院 一种含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用
CN108640929B9 (zh) * 2018-06-14 2019-09-06 绍兴文理学院 3,4,5-三甲氧基取代含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用
CN108640930B (zh) * 2018-06-14 2019-09-10 绍兴文理学院 一种对氯取代含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用
CN108516983B (zh) * 2018-06-14 2019-10-18 绍兴文理学院 一种对甲巯基取代含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用
CN108484639B (zh) * 2018-06-14 2019-10-18 绍兴文理学院 一种对氟取代含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用
CN108752364B (zh) * 2018-06-14 2019-10-15 绍兴文理学院 一种对甲氧基取代含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
WO2020125759A1 (zh) * 2018-12-21 2020-06-25 汇瀚医疗科技有限公司 作为wnt信号通路抑制剂的化合物及其医学应用
CN111349093B (zh) * 2018-12-21 2021-07-02 汇瀚医疗科技有限公司 5,6-双环化合物作为wnt信号通路抑制剂及其医学应用
CN111620874B (zh) * 2019-02-28 2022-11-15 汇瀚医疗科技有限公司 取代5,6-双杂环氨基化合物作为wnt信号通路抑制剂及其治疗应用
CN113024563B (zh) * 2019-12-24 2023-01-03 药康众拓(江苏)医药科技有限公司 嘧啶并五元杂环类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途
WO2021138450A1 (en) 2019-12-30 2021-07-08 Buto Corporation Novel small molecule shc blockers for treating liver disease and metabolic disease
WO2024094844A1 (en) 2022-11-04 2024-05-10 Astrazeneca Ab Oral formulation of n-pyridinyl acetamide derivative for treating interstitial lung disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1020237A (en) 1911-04-04 1912-03-12 Alvin L Watts Fountain-pen.
ATE236890T1 (de) 1996-12-23 2003-04-15 Bristol Myers Squibb Pharma Co Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer
SK86699A3 (en) 1996-12-23 2000-11-07 Du Pont Pharm Co Nitrogen containing heteroaromatics as factor xa inhibitors
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
SE0203654D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
JP2008515961A (ja) 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
EP2231602A1 (en) 2007-12-13 2010-09-29 Amgen, Inc Gamma secretase modulators
CN102105464A (zh) 2008-05-27 2011-06-22 德克萨斯大学***董事会 Wnt蛋白信号转导抑制剂
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
IN2014CN02646A (es) * 2011-09-14 2015-08-07 Samumed Llc
GB2513403A (en) 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
GB201322333D0 (en) * 2013-12-17 2014-01-29 Agency Science Tech & Res WNT pathway modulators
MX2017004639A (es) * 2014-10-08 2017-07-17 Redx Pharma Plc Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.
EP3204378B3 (en) 2014-10-08 2022-05-25 Redx Pharma PLC N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway

Also Published As

Publication number Publication date
EP3204381B1 (en) 2022-05-25
ES2922580T3 (es) 2022-09-16
EP3204381A1 (en) 2017-08-16
PL3204381T3 (pl) 2022-08-29
CN106795157B (zh) 2019-07-23
SI3204381T1 (sl) 2022-10-28
BR112017007218B1 (pt) 2023-10-10
JP6588976B2 (ja) 2019-10-09
RS63397B1 (sr) 2022-08-31
BR112017007218A2 (pt) 2017-12-19
AU2015329788B2 (en) 2019-10-10
SG11201702142UA (en) 2017-04-27
US11459326B2 (en) 2022-10-04
DK3204381T3 (da) 2022-07-25
JP2017530985A (ja) 2017-10-19
EP4071150A1 (en) 2022-10-12
US20190144447A1 (en) 2019-05-16
US20200407356A1 (en) 2020-12-31
WO2016055790A1 (en) 2016-04-14
CA2961740C (en) 2023-03-07
US10202375B2 (en) 2019-02-12
US20170298062A1 (en) 2017-10-19
HRP20220864T1 (hr) 2022-10-14
LT3204381T (lt) 2022-08-25
AU2015329788A1 (en) 2017-04-06
HRP20220864T8 (hr) 2023-03-17
KR20170063948A (ko) 2017-06-08
US10793562B2 (en) 2020-10-06
KR102476667B1 (ko) 2022-12-09
CA2961740A1 (en) 2016-04-14
HUE059537T2 (hu) 2022-11-28
US20230121489A1 (en) 2023-04-20
PT3204381T (pt) 2022-07-18
CN106795157A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
MX2017004639A (es) Derivados de n-piridinil acetamida como inhibidores de la via de señalizacion wnt.
PH12017500611A1 (en) N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
CR20190478A (es) Inhibidores de pd-1/pd-l1
MX2019000200A (es) Agentes antiproliferativos basados en pirimidina.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
TR201909887T4 (tr) ERK inhibitörleri olarak tieno[2,3-c]pirol-4-on türevleri.
IL261015A (en) History of methylamine as lysis oxidase inhibitors for cancer treatment
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
AU2015314007B2 (en) Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12019500070A1 (en) Uses of indolinone compounds
SG10201900564WA (en) Methods for treating cancer
PH12016501422A1 (en) Functionalised benzopyran compounds and use thereof
AU2018380132A8 (en) Tubulin inhibitors
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EA201691896A1 (ru) Соединения и способы их применения
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων